Literature DB >> 800384

A double-blind comparative trial of loxapine and trifluoperazine in acute and chronic schizophrenic patients.

L G Kiloh, S E Williams, D A Grant, P S Whetton.   

Abstract

A double-blind comparative trial of loxapine and trifluoperazine was carried out in 57 acute and chronic schizophrenic patients. In both groups of patients loxapine proved to be equivalent in its effects to trifluoperazine and there were suggestions it might be rather more effective in chronic patients. Side-effects were similar with the two drugs but anticholinergic effects, excitement, dizziness and faintness occurred rather more commonly with loxapine. Laboratory tests, urine analysis, cardiovascular and ophthalmological investigations showed no significant abnormalities.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 800384     DOI: 10.1177/030006057600400611

Source DB:  PubMed          Journal:  J Int Med Res        ISSN: 0300-0605            Impact factor:   1.671


  5 in total

Review 1.  Loxapine: a review of its pharmacological properties and therapeutic efficacy as an antipsychotic agent.

Authors:  R C Heel; R N Brogden; T M Speight; G S Avery
Journal:  Drugs       Date:  1978-03       Impact factor: 9.546

2.  Placebo response in antipsychotic clinical trials: a meta-analysis.

Authors:  Bret R Rutherford; Emily Pott; Jane M Tandler; Melanie M Wall; Steven P Roose; Jeffrey A Lieberman
Journal:  JAMA Psychiatry       Date:  2014-12-01       Impact factor: 21.596

Review 3.  Trifluoperazine for schizophrenia.

Authors:  L O Marques; M S Lima; B G O Soares
Journal:  Cochrane Database Syst Rev       Date:  2004

Review 4.  Loxapine for schizophrenia.

Authors:  A Chakrabarti; A Bagnall; P Chue; M Fenton; V Palaniswamy; W Wong; J Xia
Journal:  Cochrane Database Syst Rev       Date:  2007-10-17

5.  Revisiting loxapine: a systematic review.

Authors:  Dina Popovic; Philippe Nuss; Eduard Vieta
Journal:  Ann Gen Psychiatry       Date:  2015-04-01       Impact factor: 3.455

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.